Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2021

View Archived Issues

Boehringer Ingelheim initiates phase I study of BI-1701963 alone or in combination with BI-3011441

ERX-963 does not improve sleepiness in myotonic dystrophy type 1 patients

Enrollment opens in phase II/III study of MK-5475 in PAH

Enrollment opens in first-in-human study of OMO-103 in solid tumors

Cereno and University of Michigan collaborate on preclinical development of CS-585

Analysis of immunological and inflammatory factors associated with COVID-19 severity and progression

Xencor initiates phase I study of XmAb-564 for autoimmune diseases

X chromosome reactivation widely affects proteome

New STING receptor antagonists identified at IFM Due

Molecular Skin Therapeutics describes dual kallikrein 5/7 inhibitors

PD-1/PD-L1 interaction inhibitors identified at Bristol Myers Squibb

Recurium IP Holdings patents ERK-1 and/or ERK-2 inhibitors

Goldfinch Biopharma discovers CDK5 inhibitors

First clinical trial evaluating intravesical bacteriophage therapy for the treatment of UTIs

Atogepant statistically reduces monthly migraine days in phase III trial

First-in-class KAT6A/KAT6B inhibitor PF-9363 shows antitumor activity against ER+ breast cancer

Phase III NEPTUNO study of plitidepsin in COVID-19 receives authorization in Spain

PRT-1419 shows potent antitumor activity in preclinical models

MiR-17-92 as a therapeutic target in lupus nephritis and other autoimmune diseases

Neuromelanin MRI predicts treatment response in patients with first-episode schizophrenia

miR-206 is a prognostic marker of LGMDD2 disease progression

Phase II trial of vonoprazan regimens for H. pylori infection meets endpoints

Phase IIb/III study of masitinib in metastatic CRPC meets primary endpoint

Phase II trial evaluates ImmunityBio Anktiva with ART to inhibit HIV reservoirs

Mesoblast reports 60-day results on remestemcel-L in COVID-19 related ARDS

Preclinical through phase III, new COVID-19 therapy trials ramp up

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...